Pluri Inc. (PLUR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Pluri Inc. stock (PLUR) is currently trading at $3.05. Pluri Inc. PS ratio (Price-to-Sales) is 23.34. Analyst consensus price target for PLUR is $12.00. WallStSmart rates PLUR as Sell.
- PLUR PE ratio analysis and historical PE chart
- PLUR PS ratio (Price-to-Sales) history and trend
- PLUR intrinsic value — DCF, Graham Number, EPV models
- PLUR stock price prediction 2025 2026 2027 2028 2029 2030
- PLUR fair value vs current price
- PLUR insider transactions and insider buying
- Is PLUR undervalued or overvalued?
- Pluri Inc. financial analysis — revenue, earnings, cash flow
- PLUR Piotroski F-Score and Altman Z-Score
- PLUR analyst price target and Smart Rating
Pluri Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Pluri Inc. (PLUR) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Pluri Inc. (PLUR) Key Strengths (1)
Revenue surging 314.60% year-over-year
Supporting Valuation Data
Pluri Inc. (PLUR) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 23.3x annual revenue
Very expensive at 306.6x book value
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Pluri Inc. (PLUR) Detailed Analysis Report
Overall Assessment
This company scores 20/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 314.60%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (23.34), Price/Book (306.56) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -1022.00%, Operating Margin at -1664.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -1022.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 314.60% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PLUR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PLUR's Price-to-Sales ratio of 23.34x sits near its historical average of 25.11x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 14% below its historical high of 27.02x set in Mar 2026, and 0% above its historical low of 23.34x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~27.0x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Pluri Inc. (PLUR) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Pluri Inc. is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 1M with 315% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 315% YoY, reaching 1M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 286% of revenue (4M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Pluri Inc. maintain 315%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Pluri Inc..
Bottom Line
Pluri Inc. is a high-conviction growth story with revenue accelerating at 315% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Pluri Inc.(PLUR)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Pluri Inc. is a cutting-edge biotechnology company specializing in regenerative medicine and immunotherapy, with a strong emphasis on developing innovative cell-based therapies. Utilizing its proprietary technology platform, Pluri aims to tackle significant unmet medical needs in oncology and degenerative diseases. The company boasts a robust pipeline and strategic partnerships that position it to improve patient outcomes and capitalize on growth opportunities within the dynamic healthcare landscape. By focusing on the transformative potential of human cells, Pluri is establishing itself as a key player in the biotechnology industry, committed to advancing novel therapeutic solutions.